July 4, 2025
admin
What is the latest news of Asston Pharmaceuticals IPO?
The company will enter the market on 9th July 2025.
What is the business of Asston Pharmaceuticals IPO?
The Company is engaged in the manufacturing and export of both pharmaceutical formulations and nutraceutical products in domestic and various African markets. The Company operates under brand “Asston”. Presently, the Company is involved in the business of manufacturing and marketing of Tablets, Capsules, Oral Liquid, External Preparations (Ointment, Cream, Gel and Lotion) and Oral Powder (Sachet, Dry Syrup) etc. Apart from manufacturing products for direct sales, the Company also manufactures various pharmaceutical products for different marketers on loan license or on contract manufacturing basis. Its business is primarily conducted on a principle-to-principle basis with various marketers.
Facility has total production capacity of up to around 8-9 crore tablets per month. The syrup production capacity for nutraceuticals is approximately 37.5 kiloliters per month, while sachet production capacity ranges from 30 to 40 lakh sachets per month, depending on the powder weight per sachet.
Currently, it holds over 150 registered trademarks for its pharmaceutical formulations. Its products are distributed in various global markets, such as South Africa and the West African region.
Asston Pharmaceuticals IPO Details
|
Sector: |
|
| IPO opens on | 9 July 2025 |
| IPO closes on | 11 July 2025 |
| Issue Type | Book Built Issue IPO |
| Issue Size | 2241,000 Shares / Rs 27.56 Crore |
| * Fresh Issue | – |
| * Offer for Sale – | – Shares/ Rs.? Crore |
| Market Maker Portion | 113000 Shares |
| Net offer to Public | 2128000 Shares Rs.26.17 Crores |
| Face Value per share | Rs. 10 |
| Price Band | Rs. 115-123 |
| Employee discount | Rs. 0 per share |
| Retail Lot Size | 1000 Shares |
| Listing will at | BSE SME |
| Investor Category | Shares Offered | % | Rs. in Cr. |
| Market Maker | 113000 | ||
| QIB Shares | 1060000 | 13.04 | |
| NII (HNI) | 322000 | 3.96 | |
| Retail | 746000 | 9.18 | |
| Total | 2241000 | 100 | 27.56 |
| Application | Lots | Shares | Amount, Rs. |
| Retail (Min) | 2 | 2000 | 246,000 |
| Retail (Max) | 2 | 2000 | 246,000 |
| HNI (Min) | 3 | 3000 | 369,000 |
Who are the Promoters of Asston Pharmaceuticals IPO?
The company’s promoters are DR. ASHISH NARAYAN SAKALKAR, SAILI JAYARAM MORE AND SACHIN CHANDRAKANT BADAKH.
What are the Objects of Asston Pharmaceuticals IPO?
The Company proposes to utilize the Net Proceeds from Issue towards funding the following objects
1. Funding capital expenditure requirements towards acquiring machinery in the manufacturing unit;
2. Funding the incremental working capital requirements of the Company;
3. Repayment and/or prepayment, in part or full, of certain of its outstanding borrowings availed by the Company; and
4. General Corporate Purposes
Asston Pharmaceuticals IPO Timetable
Tentative timetable |
|
| IPO opens on | 9 July 2025 |
| IPO Closes on | 11 July 2025 |
| IPO Allotment on | 14 July 2025 |
| Refund Initiation | 15 July 2025 |
| Credit of Shares | 15 July 2025 |
| Listing on | 16 July 2025 |
| Registered Office of the Company 4th Floor, Office No A-431, Balaji Bhavan, Plot No 42A Sector-11, CBD Belapur, Navi Mumbai, Thane – 400 614, Maharashtra, India |
| Lead Manager of this IPO Sobhagya Capital Options Pvt Ltd |
| Who is the Registrar to the IPO? Maashitla Securities Pvt ltd |
Asston Pharmaceuticals IPO IPO GMP grey market premium, review, Subscription, allotment, listing estimate
Asston Pharmaceuticals IPOFinancials
Performance Indicators
How Asston Pharmaceuticals IPO IPO compares with the Peers?
# This is only coverage of News related to Grey Market Premium & subject to rates. We do not deal in grey market premium. We do not recommend dealing in Grey Market. Investment decision based on Grey Market trends can be faulty.
Asston Pharmaceuticals IPO Review by Paresh Gordhandas, CA & Research Analyst.
The company operates as a typical pharmaceutical player with no particularly novel or differentiated offerings. A closer examination of its financials reveals some concerning indicators. As of 31st March 2024, the company reported trade receivables of Rs. 16.16 crore and inventory of Rs. 1.44 crore, against a total revenue of Rs. 15.59 crore for FY 2023-24. This suggests that the entire year’s revenue remains outstanding in receivables, raising serious concerns about the company’s cash flow management and credit policies.
-
Fundamental Perspective: Avoid
-
Grey Market Sentiment: [Pending]
Quicklinks
